Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822509 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
A Phase 1 study of Recurrent Acute Myeloid Leukemia and Myeloproliferative Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 13
- Study locations
NCT01822509 is a Phase 1 study of Recurrent Acute Myeloid Leukemia and Myeloproliferative Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 71 participants, above the 57-participant average among 57 other Recurrent Acute Myeloid Leukemia trials with a reported enrollment target (25% higher). The trial reports 13 study locations across 6 states.
The verdict
NCT01822509, a Phase 1 study of Recurrent Acute Myeloid Leukemia and Myeloproliferative Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 13
- Study locations
Study Summary
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of improvement (relapsed) after donor stem cell transplant. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Study Locations (13)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Charlestown
California
- City of Hope Comprehensive Cancer Center - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- City of Hope South Pasadena - South Pasadena
Florida
- Moffitt Cancer Center-International Plaza - Tampa
- Moffitt Cancer Center - Tampa
Maine
- Eastern Maine Medical Center - Bangor
- Lafayette Family Cancer Center-EMMC - Brewer
Colorado
- Colorado Blood Cancer Institute - Denver
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2013-05-16 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822509
The ClinicalTrials.gov registry entry for NCT01822509 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 57-participant average among 57 other Recurrent Acute Myeloid Leukemia trials with a reported enrollment target (25% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01822509 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01822509 about?
NCT01822509 is a clinical study titled "Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant". This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of improvement (relapsed) after donor stem cell transplant. Immunotherapy with mono...
What is the current status of trial NCT01822509?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2013-05-16. Estimated completion is 2021-06-10.
What conditions does trial NCT01822509 study?
This clinical trial studies the following conditions: Recurrent Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT01822509?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01822509?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01822509 being conducted?
This trial has 13 study locations across California, Colorado, Florida, Georgia, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Acute Myeloid Leukemia
All registered trials for this condition
Myeloproliferative Neoplasm
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.